RATIONALE: Sibutramine, a centrally-acting selective monoamine reuptake inhibitor, has been used as an appetite suppressant drug in obesity. OBJECTIVES: To gain insight into the central nervous actions of sibutramine, brain responses to pictures of food items after sibutramine vs placebo application were assessed by functional magnetic resonance imaging (fMRI) in obese women. METHODS: In a randomized double-blind crossover design, 10 healthy obese women (BMI 31.8-39.9 kg/m(2)) received 15 mg/d of sibutramine vs placebofor 14 d. Obese participants, and a group of 10 age-matched normal weight controls, viewed pictures of food items and control objects in hungry and satiated states while lying in the MR scanner. The paradigm followed a block design. In obese participants, fMRI measurements were conducted prior and after two weeks of daily sibutramine or placebo administration, whereas control participants were scanned only at one point in time. RESULTS: Upon food item presentation, obese participants showed increased brain activity in areas related to emotional and reward processing, perceptual processing, and cognitive control as compared to normal weight controls. Sibutramine exerted a divergent satiety-dependent effect on amygdala activity in obese participants, increasing activity in the hungry state while decreasing it under conditions of satiation. CONCLUSIONS: Our results demonstrate a modulatory influence of sibutramine on amygdala activity in obese women which may underlie the appetite suppressant effects of the drug.
RCT Entities:
RATIONALE: Sibutramine, a centrally-acting selective monoamine reuptake inhibitor, has been used as an appetite suppressant drug in obesity. OBJECTIVES: To gain insight into the central nervous actions of sibutramine, brain responses to pictures of food items after sibutramine vs placebo application were assessed by functional magnetic resonance imaging (fMRI) in obesewomen. METHODS: In a randomized double-blind crossover design, 10 healthy obesewomen (BMI 31.8-39.9 kg/m(2)) received 15 mg/d of sibutramine vs placebo for 14 d. Obeseparticipants, and a group of 10 age-matched normal weight controls, viewed pictures of food items and control objects in hungry and satiated states while lying in the MR scanner. The paradigm followed a block design. In obeseparticipants, fMRI measurements were conducted prior and after two weeks of daily sibutramine or placebo administration, whereas control participants were scanned only at one point in time. RESULTS: Upon food item presentation, obeseparticipants showed increased brain activity in areas related to emotional and reward processing, perceptual processing, and cognitive control as compared to normal weight controls. Sibutramine exerted a divergent satiety-dependent effect on amygdala activity in obeseparticipants, increasing activity in the hungry state while decreasing it under conditions of satiation. CONCLUSIONS: Our results demonstrate a modulatory influence of sibutramine on amygdala activity in obesewomen which may underlie the appetite suppressant effects of the drug.
Authors: P A Tataranni; J F Gautier; K Chen; A Uecker; D Bandy; A D Salbe; R E Pratley; M Lawson; E M Reiman; E Ravussin Journal: Proc Natl Acad Sci U S A Date: 1999-04-13 Impact factor: 11.205
Authors: W Philip T James; Ian D Caterson; Walmir Coutinho; Nick Finer; Luc F Van Gaal; Aldo P Maggioni; Christian Torp-Pedersen; Arya M Sharma; Gillian M Shepherd; Richard A Rode; Cheryl L Renz Journal: N Engl J Med Date: 2010-09-02 Impact factor: 91.245
Authors: W P James; A Astrup; N Finer; J Hilsted; P Kopelman; S Rössner; W H Saris; L F Van Gaal Journal: Lancet Date: 2000 Dec 23-30 Impact factor: 79.321
Authors: Luke E Stoeckel; Jieun Kim; Rosalyn E Weller; James E Cox; Edwin W Cook; Barry Horwitz Journal: Brain Res Bull Date: 2009-05-23 Impact factor: 4.077
Authors: Victoria C Cambridge; Hisham Ziauddeen; Pradeep J Nathan; Naresh Subramaniam; Chris Dodds; Samuel R Chamberlain; Annelize Koch; Kay Maltby; Andrew L Skeggs; Antonella Napolitano; I Sadaf Farooqi; Edward T Bullmore; Paul C Fletcher Journal: Biol Psychiatry Date: 2012-12-14 Impact factor: 13.382